FDA Asks Narcolepsy Patients How Symptoms Change Over Time
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency plans a half-day meeting Sept. 24 on narcolepsy symptom burden and current treatment options, part of its patient-focused drug development initiative under PDUFA V.
You may also be interested in...
FDA Sees Challenge In Distinguishing Lung Cancer Symptoms From Drug Side Effects
At the third patient-focused drug development meeting under PDUFA V, FDA staff urged patients to try to differentiate between symptoms caused by the underlying disease and those resulting from treatment, an important distinction when it comes to assessing the efficacy and safety of new drugs.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.